Onxeo SA ONXEO-DK:Copenhagen Stock Exchange

RT Quote | Exchange | DKK
Last | 02/26/21 CET
5.24quote price arrow up+0.09 (+1.75%)
Volume
76,455
52 week range
4.85 - 5.85

...

Loading . . .

KEY STATS

  • Open5.21
  • Day High5.30
  • Day Low5.12
  • Prev Close5.15
  • 52 Week High5.85
  • 52 Week High Date02/08/21
  • 52 Week Low4.85
  • 52 Week Low Date01/28/21
  • Market Cap66.94M
  • Shares Out78.12M
  • 10 Day Average Volume71,057.67
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change34.19

RATIOS/PROFITABILITY

  • EPS (TTM)-2.36
  • P/E (TTM)-2.22
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Onxeo SA News

There is no recent news for this security.

Latest ONXEO-DK News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver...
Joseph Zakrzewski
Non-Executive Chairman
Judith Greciet
Chief Executive Officer
Nicolas Fellman
Chief Financial Officer
Philippe Maitre
Executive Vice President
Aude Michel
General Counsel
Michel Forest
Vice President
Address
49 boulevard du General Martial Valin
Paris
75015
France